Skip to main content
VBIO
NASDAQ Life Sciences

Valion Bio Reports Clean Entolimod Safety Data, Advancing to Fully Funded AFRRI Efficacy Study

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.676
Mkt Cap
$1.463M
52W Low
$0.663
52W High
$70
52W Position info
1.9% above low
Off High info
99% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

VBIO is trading near its 52-week low of $0.663 (1.9% above the low) on light trading volume (0.3× avg).

Summary

Valion Bio's Entolimod showed no treatment-related toxicity in the NIAID/AFRRI safety study, clearing the way for a fully funded AFRRI study of survival and GI recovery after radiation exposure.


Key Events · Product Development and Regulatory · VBIO

  • Entolimod Safety Study Clears

    In the AFRRI study, 20 male C57BL/6 mice received a single 0.72 mg/kg subcutaneous dose of Entolimod or saline and were observed for 14 days; investigators found no evidence of treatment-related toxicity.

  • No Toxicity Across Key Panels

    Body weight showed no statistically significant overall difference versus control (p = 0.1424), hematologic parameters stayed within normal reference ranges, and serum chemistry (BUN, creatinine, AST, ALT, ALP, glucose, total protein) showed no significant differences.

  • Next Study Fully Funded

    AFRRI is planning a fully funded therapeutic study in a GI-ARS mouse model evaluating survival and gastrointestinal tissue recovery after radiation exposure; the company did not state a start date or readout timeline.

  • Cash Still the Constraint

    The advance is externally funded, but the company previously disclosed going-concern doubt with cash of $2.1M as of the 2026-08-14 10-Q, and a $100M shelf with a $5M ATM was registered on 2026-10-08.


Analysis · VBIO · Life Sciences

Entolimod has cleared its government-funded safety phase with no treatment-related toxicity, no hematologic disruption and normal organ-function panels in the AFRRI mouse study. That moves the lead asset into a fully funded therapeutic study measuring survival and GI recovery after radiation exposure — the endpoints that matter for an FDA Animal Rule filing. For a company that previously disclosed going-concern doubt and cash of $2.1M, the value here is that the next study is externally funded, so pipeline progress does not consume the thin balance sheet. The readout is preclinical and the timeline for the efficacy data is not stated, so this de-risks the program without changing the near-term cash picture.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VBIO was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.66 to $70.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VBIO - Latest Insights

VBIO
Nov 16, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.510
Real-time Price: $0.5487 info
Change: +$0.0387 (+8%) info
Market Cap: $1.171M info
VBIO
Nov 05, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.502
Real-time Price: $0.5487 info
Change: +$0.0467 (+9%) info
Market Cap: $1.171M info
VBIO
Nov 02, 2026, 7:50 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.585
Real-time Price: $0.5487 info
Change: -$0.0363 (-6%) info
Market Cap: $1.171M info
VBIO
Oct 30, 2026, 7:50 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.6373
Real-time Price: $0.5487 info
Change: -$0.0886 (-14%) info
Market Cap: $1.171M info
VBIO
Oct 27, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.765
Real-time Price: $0.5487 info
Change: -$0.2163 (-28%) info
Market Cap: $1.171M info